J.P. Morgan Notebook, Jan. 14: Kite, Cellectis And MannKind
This article was originally published in The Pink Sheet Daily
Round-up of news and notes from the last presentations at the 2016 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.